| Keywords: |
promoter region; somatic mutation; genetics; mutation; histopathology; review; cisplatin; gemcitabine; adjuvant therapy; dna repair; gene expression profiling; tumor differentiation; pathology; fibroblast growth factor receptor 3; bladder tumor; urinary bladder neoplasms; urologic neoplasms; urothelium; diagnosis; urothelial carcinoma; dna damage response; invasive carcinoma; carcinoma, transitional cell; transitional cell carcinoma; tumor classification; mutagenesis; pathology, molecular; fibroblast growth factor receptor 2; molecular pathology; epithelial mesenchymal transition; muscle invasive bladder cancer; taxonomy; urinary tract tumor; molecular classification; humans; human; erdafitinib; infigratinib; apolipoprotein b mrna editing enzyme catalytic polypeptide like
|
